Review by Nicole on Immunotec

At the present time, MDC members are once again being transferred—this time into Immunotec. Based on past experience, continuing to follow these repeated transitions appears risky and, frankly, unwise.
Each restructuring follows the same pattern: a program is promoted aggressively, members invest time and money, and then the model is changed or abandoned. Previous transitions resulted in lost value, locked funds, and broken promises, yet the cycle continues under a new name and structure.
For those who have already experienced losses through prior MDC-related programs, there is little reason to believe this transition will be different. Instead of accountability or restitution, members are asked once again to trust a new framework without guarantees.
History matters in business. When a company repeatedly replaces one program with another while leaving unresolved issues behind, it signals instability rather than innovation.
Given this track record, continuing to follow each new transfer—including the current move to Immunotec—seems imprudent. Potential participants should carefully review past outcomes before committing further time, money, or trust.